The Discounted Cash Flow (DCF) valuation of Harvard Bioscience Inc (HBIO) is (0.29) USD. With the latest stock price at 0.43 USD, the upside of Harvard Bioscience Inc based on DCF is -168.1%.
Based on the latest price of 0.43 USD and our DCF valuation, Harvard Bioscience Inc (HBIO) is a sell. selling HBIO stocks now will result in a potential gain of 168.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.9% - 8.1% | 7.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (0.44) - 0.12 | (0.29) |
| Upside | -202.5% - -73.2% | -168.1% |